Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines].
Background: The prevalence of atrial fibrillation is increasing rapidly; however, to date, population-based data are lacking on the attributable cost of illness of atrial fibrillation from a societal perspective, including both...
Objectives: To address the relationship between years lived with a disability (YLDs), prevalence and cost of neurological diseases, and to test whether there is a European North–South gradient for national health expenditure, disability, costs and prevalence of neurological diseases.
Objective: To evaluate the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background therapy.
Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies.
NICE has recommended the use of Saxenda (liraglutide), from Novo Nordisk, for treating obesity.
This review evaluates the current literature regarding efficacy of monoclonal antibodies for the treatment of CRSwNP and considers this efficacy in light of the cost implications to individuals and society.
The purpose of this study was to estimate the prevalence and cost of illness of asthma in Germany by retrospectively analysing routine health insurance data.
Objective: To evaluate clinical utility of therapeutic drug monitoring for ustekinumab in patients with psoriasis.
A new analysis of real-world data has shown that switching to Tresiba (insulin degludec) is highly cost-effective and cost-saving for...